Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2176 to 2190 of 7682 results

  1. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development [GID-TA11326] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions

    Diagnostics guidance
    Published
    11 November 2015
    View recommendations

    Sections for DG19

  3. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer

    Diagnostics guidance
    Published
    9 May 2024
    View recommendations

    Sections for DG58

  4. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development [GID-TA11161] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. High-dose aflibercept for treating wet age-related macular degeneration TS ID 10590

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Aflibercept for untreated diabetic macular oedema TS ID 10621

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Lymphatico-venous anastomosis for chronic lymphoedema

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  9. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer ID 6436

    Awaiting development [GID-TA11532] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  15. Suspected sepsis: recognition, diagnosis and early management

    In development [GID-NG10412] Expected publication date: 13 August 2025

    NICE guideline
    In development